BUDIPINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H27N.ClH
Molecular Weight	329.907
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=USUUKNCFNKZGEY-UHFFFAOYSA-N

InChI=1S/C21H27N.ClH/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19;/h4-13H,14-17H2,1-3H3;1H

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904 | DOI 10.1007/978-3-7091-6360-3 , Przuntek H., Müller T., 'Diagnosis and Treatment of Parkinson’s Disease - State of the Art' (2013), p. 88, Retrieved from https://books.google.com/books?id=G6DzCAAAQBAJ&dq

Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-B enzyme and stimulating aromatic L-amino acid decarboxylase. Also the drug inhibits the dopamine re-uptake and has weak affinity to NMDA and muscarinic receptors. Budipine passes the blood-brain barrier, is metabolized by hydroxylation, and is excreted by both in urine and feces within 24 h.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Amine oxidase [flavin-containing] B 11 Target ID: P27338 Gene ID: 4129.0 Gene Symbol: MAOB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904	Inhibitor 8297	5.0 µM [IC50]
Sodium-dependent dopamine transporter 42 Target ID: Q01959 Gene ID: 6531.0 Gene Symbol: SLC6A3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904	Blocker 537	11.0 µM [IC50]
Aromatic-L-amino-acid decarboxylase 5 Target ID: P20711 Gene ID: 1644.0 Gene Symbol: DDC Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 226 Sources: https://www.medikamente-per-klick.de/images/ecommerce/08/44/08449633_2011-04_de_o.pdf	Primary		Approved 8429	PARKINSAN Approved Use For combination therapy of Parkinson's disease. Launch Date 1996

PubMed

Title	Date	PubMed
[Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines].	1984	6539602
Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats.	2005 Jul	15834446
The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.	2005 Jul 22-29	15936515
[Diagnosis and therapy of idiopathic Parkinson's disease].	2006 May 15	20104716
A new strategy for antidepressant prescription.	2010	21151361
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].	2010 Mar	20195940

Patents

Sample Use Guides

In Vivo Use Guide

The dosage is determined individually. The treatment should start with 3 times daily 10 mg budipine hydrochloride. If necessary, the daily dose should be increased at the earliest after 1 week to 3 x 20 mg budipine hydrochloride or 2 x 30 mg budipine hydrochloride.

Route of Administration: Oral

In Vitro Use Guide

10(-7), 10(-8), 10(-9) mol/l of budipine significantly reduced release of TNF-alpha and Il-6 in PBMC and decreased apoptotic cell death after 50 hours and 74 hours in the SH-SY 5Y cells.

Name

Type

Language

BUDIPINE HYDROCHLORIDE

Common Name

English

PARKINSAN

Brand Name

English

BUDIPINE HYDROCHLORIDE [MI]

Common Name

English

1-TERT-BUTYL-4,4-DIPHENYLPIPERIDINIUM CHLORIDE

Systematic Name

English

Budipine Hydrochloride [WHO-DD]

Common Name

English

Code System Code Type Description

MERCK INDEX

m2747